Natrecor in Pulmonary Hypertension (NCT00075179) | Clinical Trial Compass
TerminatedPhase 4
Natrecor in Pulmonary Hypertension
Stopped: Low accrual.
United States15 participantsStarted 2003-12-31
Plain-language summary
The goal of this clinical research study is to learn if the drug nesiritide (Natrecor) is effective in lowering the pressure in your lungs.
The primary objective of this study is to establish that Nesiritide (Natrecor) is effective in reducing pulmonary hypertension (PHTN) acutely as measured by a 20% reduction in the mean pulmonary arterial (PA) pressure. The secondary objectives will include: improvement in pulmonary vascular resistance (PVR), patient symptoms, exercise tolerance, frequency of toxicity, and surgeon's willingness to proceed with operation.
Who can participate
Age range18 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Ages 18 to 85 years old.
✓. Evidence of underlying lung disease by history and physical and/or chest x-ray and/or pulmonary function testing (PFT's).
✓. PHTN documented by Doppler Echocardiography ( Done with in last 30 days)
✓. Must be able to give an informed consent.
Exclusion criteria
✕. Patients with clinically significant hypotension (defined as a systolic blood pressure (SBP) \<90).
✕. Active infection or sepsis as defined by fever and need for IV antibiotics.
✕. Creatinine greater than 3.0 mg/dl
✕. Significant valvular disease as a cause for the PHTN.
✕. Severe Thrombocytopenia (as defined by platelets less than 20,000 or INR \> 1.6.
✕. Left Ventricle Ejection Fraction (LVEF) \<40% (must be done with in the last 30 days prior to signing consent).
What they're measuring
1
Number Patients with 20% reduction in mean pulmonary arterial (PA) pressure to measure pulmonary hypertension (PHTN)
Timeframe: Baseline and 15 and 30 minutes after end of procedure